Market Research Logo

U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2022)

U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2022)

Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person’s ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.

MDD is the most common mental disorder in the U.S. Approximately 16 million American adults suffer from the major depressive disorder and about one-third of the MDD patient remain untreated. The number of treated patients is projected to rise on account of better medical access and rising awareness regarding depression. There are few potential drugs in development that are being developed with improved efficacy and safety for the treatment of MDD and are expected to contribute significantly to the market growth in the U.S.

The U.S. MDD market is expected to grow in future due to rising aging population, growing MDD prevalence, growing female prevalence, increasing prescription drugs spending, high unmet needs, and escalating mental health expenditure. Key trends of this market include rising number of mental health programs, increasing awareness, rapid drugs in development and direct to customer advertising. However, there are some factors which can hinder the growth of the market which includes patent expiry of drugs, stringent regulations, side effects associated with antidepressants and availability of alternative therapies.

The report “U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. market. The report profiles the key players in the market including. Pfizer Inc., AstraZeneca, Eli Lily and Company and Lundbeck.


1. Market Overview
1.1 Introduction
Table 1: Types of Depression
1.2 Causes of MDD
1.3 Symptoms of MDD
Table 2: Causes & Symptoms of Depression
1.4 Diagnosis & Treatment of MDD
2. The U.S. MDD Market
2.1 The U.S. MDD Market by Value
Table 3: The U.S. MDD Market by Value (2017-2022)
2.2 The U.S. MDD Market by Drug Type
Table 4: The U.S. MDD Market by Drug Type (2017)
2.3 The U.S. Anti-Depressants Drugs Market
Table 5: The U.S. Anti-Depressants Drugs Market (2017-2022)
2.4 The U.S. Antipsychotics Drugs Market
Table 6: The U.S. Antipsychotics Drugs Market (2017-2022)
2.5 The U.S. Top Psychiatric Drugs Revenue
Table 7: The U.S. Top Psychiatric Drugs Revenue (2016)
2.6 The U.S. MDD Prevalence Forecast by Age
Table 8: The U.S. MDD Prevalence Forecast by Age (2017-2022)
2.7 The U.S. MDD Patient Population Forecast
Table 9: The U.S. MDD Patient Population Forecast (2017-2022)
2.8 The U.S. MDD Treated Patient Population Forecast
Table 10: The U.S. MDD Treated Patient Population Forecast (2017-2022)
2.9 The U.S. MDD Patient Treatment
Table 11: The U.S. MDD Patient Treatment (2017)
2.10 The U.S. MDD Patient Population with TMS Criteria
Table 12: The U.S. MDD Patient Population with TMS Criteria (2017-2022)
2.11 The U.S. MDD Patient Share by Symptoms
Table 13: The U.S. MDD Patient Share by Symptoms (2017)
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Growing Aging Population
Table 14: The U.S. Aging Population (2013-2017)
3.1.2 Rising Female Population
Table 15: Female Population in the U.S. (2013-2017)
3.1.3 Increasing Spending on Prescription Drugs
Table 16: Prescription Drug Spending in the U.S. (2013-2017)
3.1.4 Increasing Prevalence of Depression
Table 17: Percentage of U.S. Youth with MDD by Gender (2013-2017)
3.1.5 Growing Mental Health Expenditure
Table 18: The U.S. Mental Health Expenditure Forecast (2017-2022)
3.1.6 Unmet Need
3.2 Key Trends & Developments
3.2.1 Increasing Awareness for Depression
3.2.2 Direct to Customer Advertising
3.2.3 Rapid Acting Drugs In Development
Table 19: Drug Pipeline for Treatment of MDD in the U.S.
3.2.4 Rising Number of Mental Health Programs
3.3 Challenges
3.3.1 Stringent Drug Regulations
3.3.2 Patent Expiry of Drugs
3.3.3 Complications and Side Effects associated with Anti-depressants
Table 20: Side Effects of Anti-Depressant Drugs
3.3.4 Availability of Other Therapies such as Meditation and Psychotherapy
4. Competitive Landscape
4.1 Global MDD Market
4.1.1 Revenue Comparison of Top Companies
Table 21: Revenue Comparison of Top Companies (2017)
4.1.2 Market Capitalization Comparison of Top Companies
Table 22: Market Capitalization Comparison of Top Companies (2017)
4.1.3 Research & Development Expenditure Comparison of Top Companies
Table 23: Research & Development Expenditure of Top Companies (2017)
4.2 The U.S. MDD Market
4.2.1 The U.S. Anti-Depressants Market Comparison by Product Profile
Table 24: The U.S. Anti-Depressants Market Comparison by Product Profile (2017)
4.2.2 The U.S. Anti-Psychotics Market Comparison by Product Profile
Table 25: The U.S. Anti-Psychotics Market Comparison by Product Profile (2017)
5. Company Profiles
5.1 Pfizer, Inc.
5.1.1 Business Overview
Table 26: Pfizer Inc. Revenue by Segment (2017)
5.1.2 Financial Overview
Table 27: Pfizer Inc. Revenue and Net Income (2013-2017)
5.1.3 Business Strategies
Table 28: Pfizer Inc. R&D Expenditure (2015-2017)
5.2 Eli Lilly and Company
5.2.1 Business Overview
Table 29: Eli Lilly and Company Revenue by Segments (2017)
5.2.2 Financial Overview
Table 30: Eli Lilly and Company Revenue and Net Income (2013-2017)
5.2.3 Business Strategies
Table 31: Eli Lilly and Company Research and Development Expenditure (2015-2017)
5.3 AstraZeneca
5.3.1 Business Overview
Table 32: AstraZeneca Revenue by Segments (2017)
5.3.2 Financial Overview
Table 33: AstraZeneca Revenue and Net Profit (2013-2017)
5.3.3 Business Strategies
5.4 Lundbeck
5.4.1 Business Overview
Table 34: Lundbeck Revenue by Products (2017)
5.4.2 Financial Overview
Table 35: Lundbeck Revenue and Net Profit (2013-2017)
5.4.3 Business Strategies
Table 36: Lundbeck Research and Development Expenditure (2015-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report